» Articles » PMID: 37880722

Shifting Drug Markets in North America - a Global Crisis in the Making?

Overview
Publisher Biomed Central
Specialty Health Services
Date 2023 Oct 26
PMID 37880722
Authors
Affiliations
Soon will be listed here.
Abstract

Understanding drug market dynamics and their underlying driving factors is paramount to developing effective responses to the overdose crisis in North America. This paper summarises the distinct drug market trends observed locally and internationally over the past decade to extrapolate future drug market trajectories. The emergence of fentanyl on North American street markets from 2014 onwards led to a shift of street drug use patterns. Previously perceived as contaminants, novel synthetic opioids became the drugs of choice and a trend towards higher potency was observed across various substance classes. The diversification of distribution strategies as well as the regionalisation and industrialisation of production followed basic economic principles that were heavily influenced by prosecution and policy makers. Particularly, the trend towards higher potency is likely most indicative of what to expect from future illicit drug market developments. Nitazenes and fentanyl-analogues, several times more potent than fentanyl itself, are increasingly detected in toxicological testing and have the potential of becoming the drugs of choice in the future. The dynamic of drug import and local production is less clear and influenced by a multitude of factors like precursor availability, know-how, infrastructure, and the success of local drug enforcement strategies. Drug market dynamics and the current trajectory towards ultrapotent opioids need to be recognised by legislation, enforcement, and the health care system to prepare effective responses. Without significant improvements in treatment access, the implementation of preventative approaches and early warning systems, the mortality rate will continue to increase. Furthermore, there is no mechanism in place preventing the currently North American focused overdose crisis to spread to other parts of the globe, particularly Europe. A system of oversight, research, and treatment is needed to address mortality rates of historic proportions and prevent further harm.

Citing Articles

"Sometimes I'm interested in seeing a fuller story to tell with numbers" Implementing a forecasting dashboard for harm reduction and overdose prevention: a qualitative assessment.

Gray J, Krieger M, Skinner A, Parker S, Basta M, Reichley N BMC Public Health. 2025; 25(1):915.

PMID: 40055691 PMC: 11887322. DOI: 10.1186/s12889-025-22004-y.


Chronic pain among primary fentanyl users: The concept of self-medication.

Kim J, Hayati D, Zamany M, Choi F, Jang K, Ignaszewski M Eur J Pain. 2024; 29(1):e4753.

PMID: 39503238 PMC: 11610678. DOI: 10.1002/ejp.4753.


Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit.

Weiner S, Little K, Yoo J, Flores D, Hildebran C, Wright D JAMA Netw Open. 2024; 7(7):e2423954.

PMID: 39037812 PMC: 11265135. DOI: 10.1001/jamanetworkopen.2024.23954.


Associations among drug acquisition and use behaviors, psychosocial attributes, and opioid-involved overdoses.

Swartz J, Zhao P, Jacobucci R, Watson D, Mackesy-Amiti M, Franceschini D BMC Public Health. 2024; 24(1):1692.

PMID: 38918744 PMC: 11197316. DOI: 10.1186/s12889-024-19217-y.


Ending the overdose epidemic by ending the war on drug users: Can this work?.

Leyton M, Krausz R J Psychiatry Neurosci. 2024; 49(1):E77-E80.

PMID: 38383036 PMC: 10890790. DOI: 10.1503/jpn.240003.


References
1.
Price O, Man N, Sutherland R, Bruno R, Dietze P, Salom C . Disruption to Australian heroin, methamphetamine, cocaine and ecstasy markets with the COVID-19 pandemic and associated restrictions. Int J Drug Policy. 2023; 113:103976. PMC: 9932690. DOI: 10.1016/j.drugpo.2023.103976. View

2.
Karamouzian M, Papamihali K, Graham B, Crabtree A, Mill C, Kuo M . Known fentanyl use among clients of harm reduction sites in British Columbia, Canada. Int J Drug Policy. 2020; 77:102665. DOI: 10.1016/j.drugpo.2020.102665. View

3.
Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T . One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction. 2018; 114(1):103-111. DOI: 10.1111/add.14442. View

4.
Fogarty M, Vandeputte M, Krotulski A, Papsun D, Walton S, Stove C . Toxicological and pharmacological characterization of novel cinnamylpiperazine synthetic opioids in humans and in vitro including 2-methyl AP-237 and AP-238. Arch Toxicol. 2022; 96(6):1701-1710. DOI: 10.1007/s00204-022-03257-7. View

5.
Seely K, Lapoint J, Moran J, Fattore L . Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39(2):234-43. PMC: 3936256. DOI: 10.1016/j.pnpbp.2012.04.017. View